Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CNTO 6785 in Moderate to Severe COPD (Phase 2, Randomized, Placebo-controlled)
2012-003607-36Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jul 2013
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of CNTO 6785 in chronic obstructive pulmonary disease (COPD), sponsored by Janssen Pharmaceutical. Started Jul 2013; status: completed.
02
Drugs
CNTO 6785
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2012-003607-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-003607-36.